Abstract
Clinical (123)I-2-β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane ((123)I-FP-CIT) SPECT studies are commonly performed and reported using visual evaluation of tracer binding, an inherently subjective method. Increased objectivity can potentially be obtained using semiquantitative analysis. In this study, we assessed whether semiquantitative analysis of (123)I-FP-CIT tracer binding created more reproducible clinical reporting. A secondary aim was to determine in what form semiquantitative data should be provided to the reporter.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of nuclear medicine : official publication, Society of Nuclear Medicine |
| Vol/bind | 54 |
| Udgave nummer | 5 |
| Sider (fra-til) | 714-22 |
| Antal sider | 9 |
| ISSN | 0161-5505 |
| DOI | |
| Status | Udgivet - maj 2013 |
Fingeraftryk
Dyk ned i forskningsemnerne om 'Value of semiquantitative analysis for clinical reporting of 123I-2-β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane SPECT studies'. Sammen danner de et unikt fingeraftryk.Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS